Table 1 General characteristics of trials on glaucoma interventions (n = 79) with results both in the ClinicalTrials.gov and the publication.
No. (%) | |
|---|---|
Primary completion | |
Before FDAA Final Rulea | 58 (73) |
After FDAA Final Rulea | 21 (27) |
Trial phase | |
2 | 16 (20) |
3 | 34 (43) |
4 | 29 (37) |
Masking | |
None (Open Label) | 23 (29.1) |
Single Blinded | 11 (13.9) |
Double Blinded | 22 (27.9) |
Triple Blinded | 12 (15.2) |
Quadruple Blinded | 11 (13.9) |
Control | |
None | 16 (20.3) |
Active | 50 (63.3) |
Placebo | 8 (10.1) |
Both | 5 (6.3) |
Intervention model | |
Parallel Assignment | 57 (72.2) |
Single Assignment | 17 (21.5) |
Crossover Assignment | 5 (6.3) |
Industry sponsored | |
Yes | 72 (91) |
No | 7 (9) |
Publication before last update on ClinicalTrials.gov | |
Yes | 30 (37) |
No | 49 (62) |
Type of intervention | |
Fixed combination eye drops | 28 (35) |
Prostaglandin analogues eye drops | 22 (27) |
Rho-inhibitor eye drops | 7 (9) |
Sustained releasing medications | 9 (11) |
Surgery | 4 (5) |
Anti-VEGF medication | 3 (4) |
Experimental medications | 3 (4) |
Otherb | 3(4) |
